Key facts
- This page summarizes John E. Celentano's Form 4 filing for Teligent, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Jul 2021, 17:04.
John E. Celentano - 21 Jul 2021 Form 4 Insider Report for Teligent, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 21 Jul 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ John E. Celentano
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
John E. Celentano filed Form 4 for Teligent, Inc. on 22 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLGT
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 21 Jul 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock
Footnote F2
The shares underlying the derivative securities shall vest fully on the first anniversary of grant.
Footnote F3
Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50.